The market in Sydney wrapped up at 17:00 AEDT, Feb 17, 2026.
- CSL slipped 0.4% to close at A$151.56, while the ASX 200 managed to notch a modest gain
- CSL snapped up 75,949 of its own shares on Monday, according to a daily filing.
- After a turbulent month, attention remains locked on the pace of buybacks and those March dividend dates.
CSL Limited ASX:CSL slipped 0.4% to finish at A$151.56 on Tuesday, lagging behind the S&P/ASX 200’s 0.2% gain. The stock has lost roughly 14% since early February, hit by a steep drop during profit season.
CSL snapped up 75,949 shares in Monday’s buy-back, spending A$11.6 million, according to its latest daily filing. That brings the tally for its on-market repurchase program to about 3.22 million shares so far. Total spend? Roughly A$619 million. CSL has flagged the buy-back could go as high as US$750 million.
The buyback stands out right now—one of the only tangible props for investors keeping score daily as they wait to see if the back half delivers. CSL’s been working to calm nerves after some rough headlines and lower targets shook things up.
Last week, the company posted underlying net profit after tax (NPATA) of roughly US$1.9 billion for the six months ended Dec. 31, a 7% decline. The measure, which omits certain one-off items, came in under pressure. 2026 guidance held steady: revenue growth is still pegged at 2%-3%, and NPATA growth at 4%-7% in constant currency terms, so that’s without factoring in FX moves. “We are clearly not satisfied with our performance,” said Chief Financial Officer Ken Lim, who pointed to a planned second-half push driven by immunoglobulin and albumin.
Leadership changes are drawing attention. Earlier this month, CSL announced chief executive Paul McKenzie’s retirement. Gordon Naylor, a former senior executive and director, steps in as interim CEO while the board looks for a permanent successor. “Now is the right time for new leadership,” chair Brian McNamee said. Naylor described his “immediate priority” as executing the transformation plan and delivering for shareholders.
The route forward isn’t straightforward. CSL’s earnings remain exposed to plasma collection and manufacturing hurdles, as well as pricing and reimbursement swings, regulatory shifts, and a new wave of competition—including generics that now threaten parts of its Vifor portfolio. Currency volatility also stays in play.
Product headlines have also been in play. Back on Feb. 15, Reuters flagged that CSL announced neffy—its adrenaline nasal spray—received approval for anaphylaxis treatment in Australia.
Dividends up next. CSL put forward an interim payout of US$1.30 per share; the ex-dividend date lands on March 10, and shareholders can expect payment by April 9. The company noted that the AUD equivalent will come out March 13.
Looking ahead to the next session and through the week, investors are eyeing CSL to see if its buying pace holds steady and if the shares find their footing following the slide after results. Then, the focus shifts to the March dividend schedule, along with any new details on the progress of the second-half “growth plan.”
